Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer

Table 1

Patient demographics and clinical characteristics.

	Neoadjuvant chemotherapy		𝑃 value
	No; 𝑁 (%)	Yes; 𝑁 (%)
Gender			0.87
Male	70 (76%)	66 (76%)
Female	21 (24%)	21 (24%)
Age			0.02
<60	21 (23%)	32 (37%)
60–69	33 (36%)	35 (40%)
>70	37 (41%)	20 (23%)
Race			0.99
Caucasian	79 (89%)	75 (88%)
Other	10 (11%)	10 (12%)
Complete TURBT			0.28
Yes	32 (35%)	39 (46%)
No	53 (58%)	43 (51%)
Unknown	6 (7%)	3 (4%)
Cardiac disease			0.13
Yes	23 (25%)	14 (16%)
No	68 (75%)	73 (84%)
Creatinine			0.49
≤1.0	47 (53%)	51 (59%)
>1.0	41 (47%)	36 (41%)